ReviewCancers2022
Metabolic Imaging in B-Cell Lymphomas during CAR-T Cell Therapy.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.
- The prognostic utility ofFrontiers in immunology · 2024Pooled it
- Metabolic tumor volume and the survival of patients with Non-Hodgkin lymphoma treated with chimeric antigen receptor T cell therapy: a meta-analysis.Frontiers in immunology · 2024Pooled it
- A Critical Review of PET/CT Assessment After CAR-T Cell Therapy in Large B-Cell Lymphoma, Limitations of Current Criteria, Emerging Biomarkers, and a Framework for Standardised Evaluation.Journal of multidisciplinary healthcare · 2026Review
- Imaging Immunotherapy.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- The predictive power of baseline metabolic and volumetric [European journal of radiology open · 2025Article
- [European journal of radiology open · 2025Article
- Editorial: Enhancing CAR T-cell therapy with imaging.Frontiers in immunology · 2025Article
- FDG-PET in Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy Toxicity: A Systematic Review.Cancers · 2024Review
- More than Just Skin-Deep: A Review of Imaging's Role in Guiding CAR T-Cell Therapy for Advanced Melanoma.Diagnostics (Basel, Switzerland) · 2023Review
- FDG-PET/CT in the Monitoring of Lymphoma Immunotherapy Response: Current Status and Future Prospects.Cancers · 2023Review
- PET/CT in the Evaluation of CAR-T Cell Immunotherapy in Hematological Malignancies.Molecular imagingReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor-engineered (CAR) T cells are emerging powerful therapies for patients with refractory/relapsed B-cell lymphomas. [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.